JP2006511596A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006511596A5 JP2006511596A5 JP2005501006A JP2005501006A JP2006511596A5 JP 2006511596 A5 JP2006511596 A5 JP 2006511596A5 JP 2005501006 A JP2005501006 A JP 2005501006A JP 2005501006 A JP2005501006 A JP 2005501006A JP 2006511596 A5 JP2006511596 A5 JP 2006511596A5
- Authority
- JP
- Japan
- Prior art keywords
- hydroxy
- ethyl
- carboxamide
- indole
- amino
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 33
- 150000001875 compounds Chemical class 0.000 claims 24
- 229910052739 hydrogen Inorganic materials 0.000 claims 21
- 239000001257 hydrogen Substances 0.000 claims 21
- 208000006673 asthma Diseases 0.000 claims 19
- 150000003839 salts Chemical class 0.000 claims 17
- 206010006451 bronchitis Diseases 0.000 claims 15
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 12
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 11
- 201000009267 bronchiectasis Diseases 0.000 claims 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 9
- 150000002431 hydrogen Chemical class 0.000 claims 9
- 239000012453 solvate Substances 0.000 claims 9
- 230000000155 isotopic effect Effects 0.000 claims 8
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 8
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 7
- -1 hydroxy, methyl Chemical group 0.000 claims 7
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 6
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims 6
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 6
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 6
- 239000003814 drug Substances 0.000 claims 5
- 125000001475 halogen functional group Chemical group 0.000 claims 5
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 4
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 208000035475 disorder Diseases 0.000 claims 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 4
- 201000010659 intrinsic asthma Diseases 0.000 claims 3
- 230000001717 pathogenic effect Effects 0.000 claims 3
- 208000023504 respiratory system disease Diseases 0.000 claims 3
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims 2
- 208000000884 Airway Obstruction Diseases 0.000 claims 2
- 206010006458 Bronchitis chronic Diseases 0.000 claims 2
- 206010014561 Emphysema Diseases 0.000 claims 2
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims 2
- 230000001154 acute effect Effects 0.000 claims 2
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 claims 2
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims 2
- 125000000217 alkyl group Chemical group 0.000 claims 2
- 229940124748 beta 2 agonist Drugs 0.000 claims 2
- 208000007451 chronic bronchitis Diseases 0.000 claims 2
- 208000024711 extrinsic asthma Diseases 0.000 claims 2
- VKOBVWXKNCXXDE-UHFFFAOYSA-N icosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCC(O)=O VKOBVWXKNCXXDE-UHFFFAOYSA-N 0.000 claims 2
- 208000015181 infectious disease Diseases 0.000 claims 2
- 230000002458 infectious effect Effects 0.000 claims 2
- 230000002757 inflammatory effect Effects 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 230000000414 obstructive effect Effects 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 125000004207 3-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(OC([H])([H])[H])=C1[H] 0.000 claims 1
- JIIXGDGLWIDEHT-CLYVBNDRSA-N 5-[(2r)-2-[[(2r)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl]amino]propyl]-n-[(2-methoxyphenyl)methyl]-1h-indole-2-carboxamide Chemical compound COC1=CC=CC=C1CNC(=O)C1=CC2=CC(C[C@@H](C)NC[C@H](O)C=3C=C(CO)C(O)=CC=3)=CC=C2N1 JIIXGDGLWIDEHT-CLYVBNDRSA-N 0.000 claims 1
- JHRNSGOBXJUMPH-WRHNGFHOSA-N 5-[(2r)-2-[[(2r)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl]amino]propyl]-n-[(3-methoxyphenyl)methyl]-1h-indole-2-carboxamide Chemical compound COC1=CC=CC(CNC(=O)C=2NC3=CC=C(C[C@@H](C)NC[C@H](O)C=4C=C(CO)C(O)=CC=4)C=C3C=2)=C1 JHRNSGOBXJUMPH-WRHNGFHOSA-N 0.000 claims 1
- FDAKLYKEIOPOKK-XBBWARJSSA-N 5-[(2r)-2-[[(2r)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl]amino]propyl]-n-[2-(3-methoxyphenyl)ethyl]-1h-indole-2-carboxamide Chemical compound COC1=CC=CC(CCNC(=O)C=2NC3=CC=C(C[C@@H](C)NC[C@H](O)C=4C=C(CO)C(O)=CC=4)C=C3C=2)=C1 FDAKLYKEIOPOKK-XBBWARJSSA-N 0.000 claims 1
- 206010003557 Asthma exercise induced Diseases 0.000 claims 1
- 206010003645 Atopy Diseases 0.000 claims 1
- 208000035143 Bacterial infection Diseases 0.000 claims 1
- 206010006448 Bronchiolitis Diseases 0.000 claims 1
- 206010006482 Bronchospasm Diseases 0.000 claims 1
- 206010011416 Croup infectious Diseases 0.000 claims 1
- 208000004657 Exercise-Induced Asthma Diseases 0.000 claims 1
- 206010017533 Fungal infection Diseases 0.000 claims 1
- 208000016300 Idiopathic chronic eosinophilic pneumonia Diseases 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 208000031888 Mycoses Diseases 0.000 claims 1
- 208000010362 Protozoan Infections Diseases 0.000 claims 1
- 208000037656 Respiratory Sounds Diseases 0.000 claims 1
- 208000036142 Viral infection Diseases 0.000 claims 1
- 206010047924 Wheezing Diseases 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 239000000654 additive Substances 0.000 claims 1
- 230000000996 additive effect Effects 0.000 claims 1
- 230000036428 airway hyperreactivity Effects 0.000 claims 1
- 239000013566 allergen Substances 0.000 claims 1
- 201000009961 allergic asthma Diseases 0.000 claims 1
- 230000001580 bacterial effect Effects 0.000 claims 1
- 208000022362 bacterial infectious disease Diseases 0.000 claims 1
- 102000016966 beta-2 Adrenergic Receptors Human genes 0.000 claims 1
- 108010014499 beta-2 Adrenergic Receptors Proteins 0.000 claims 1
- 230000007885 bronchoconstriction Effects 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 201000009323 chronic eosinophilic pneumonia Diseases 0.000 claims 1
- 201000010549 croup Diseases 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 230000007613 environmental effect Effects 0.000 claims 1
- 208000024695 exercise-induced bronchoconstriction Diseases 0.000 claims 1
- 230000003325 follicular Effects 0.000 claims 1
- 230000002538 fungal effect Effects 0.000 claims 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims 1
- 208000030603 inherited susceptibility to asthma Diseases 0.000 claims 1
- 230000002427 irreversible effect Effects 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 238000002483 medication Methods 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- WTBGOYCHEVMMHF-CLYVBNDRSA-N n-[(2,6-dimethoxyphenyl)methyl]-5-[(2r)-2-[[(2r)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl]amino]propyl]-1h-indole-2-carboxamide Chemical compound COC1=CC=CC(OC)=C1CNC(=O)C1=CC2=CC(C[C@@H](C)NC[C@H](O)C=3C=C(CO)C(O)=CC=3)=CC=C2N1 WTBGOYCHEVMMHF-CLYVBNDRSA-N 0.000 claims 1
- 208000007892 occupational asthma Diseases 0.000 claims 1
- 230000008506 pathogenesis Effects 0.000 claims 1
- 230000001991 pathophysiological effect Effects 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 230000000750 progressive effect Effects 0.000 claims 1
- 230000002062 proliferating effect Effects 0.000 claims 1
- 125000006239 protecting group Chemical group 0.000 claims 1
- 208000002815 pulmonary hypertension Diseases 0.000 claims 1
- 230000029058 respiratory gaseous exchange Effects 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 125000006493 trifluoromethyl benzyl group Chemical group 0.000 claims 1
- 230000009385 viral infection Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20020292513 EP1407769A1 (en) | 2002-10-11 | 2002-10-11 | Indole derivatives as beta-2 agonists |
| EP03290069A EP1440966A1 (en) | 2003-01-10 | 2003-01-10 | Indole derivatives useful for the treatment of diseases |
| PCT/IB2003/004441 WO2004032921A1 (en) | 2002-10-11 | 2003-10-06 | Indole derivatives as beta-2 agonists |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2006511596A JP2006511596A (ja) | 2006-04-06 |
| JP2006511596A5 true JP2006511596A5 (enExample) | 2006-06-22 |
| JP4490911B2 JP4490911B2 (ja) | 2010-06-30 |
Family
ID=32095049
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2005501006A Expired - Fee Related JP4490911B2 (ja) | 2002-10-11 | 2003-10-06 | β−２アゴニストとしてのインドール誘導体 |
Country Status (25)
| Country | Link |
|---|---|
| EP (1) | EP1556034B1 (enExample) |
| JP (1) | JP4490911B2 (enExample) |
| KR (1) | KR20050047552A (enExample) |
| AP (1) | AP2005003283A0 (enExample) |
| AR (1) | AR041566A1 (enExample) |
| AT (1) | ATE392206T1 (enExample) |
| AU (1) | AU2003269316A1 (enExample) |
| BR (1) | BR0315234A (enExample) |
| CA (1) | CA2499314C (enExample) |
| CO (1) | CO5550421A2 (enExample) |
| DE (1) | DE60320439T2 (enExample) |
| EA (1) | EA200500618A1 (enExample) |
| EC (1) | ECSP055780A (enExample) |
| ES (1) | ES2302938T3 (enExample) |
| IS (1) | IS7751A (enExample) |
| MA (1) | MA27452A1 (enExample) |
| MX (1) | MXPA05003866A (enExample) |
| NO (1) | NO20051406L (enExample) |
| OA (1) | OA12938A (enExample) |
| PA (1) | PA8586001A1 (enExample) |
| PE (1) | PE20040775A1 (enExample) |
| PL (1) | PL376396A1 (enExample) |
| TW (1) | TW200424171A (enExample) |
| UY (1) | UY28013A1 (enExample) |
| WO (1) | WO2004032921A1 (enExample) |
Families Citing this family (67)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR028948A1 (es) | 2000-06-20 | 2003-05-28 | Astrazeneca Ab | Compuestos novedosos |
| EP1460064A1 (en) | 2003-03-14 | 2004-09-22 | Pfizer Limited | Indole-2-carboxamide derivatives useful as beta-2 agonists |
| GB0312832D0 (en) * | 2003-06-04 | 2003-07-09 | Pfizer Ltd | 2-amino-pyridine derivatives useful for the treatment of diseases |
| GB0401334D0 (en) | 2004-01-21 | 2004-02-25 | Novartis Ag | Organic compounds |
| WO2005092841A1 (en) * | 2004-03-23 | 2005-10-06 | Pfizer Limited | Compounds having beta-agonist activity |
| GB0411056D0 (en) | 2004-05-18 | 2004-06-23 | Novartis Ag | Organic compounds |
| AR049384A1 (es) | 2004-05-24 | 2006-07-26 | Glaxo Group Ltd | Derivados de purina |
| GT200500281A (es) | 2004-10-22 | 2006-04-24 | Novartis Ag | Compuestos organicos. |
| GB0424284D0 (en) | 2004-11-02 | 2004-12-01 | Novartis Ag | Organic compounds |
| GB0426164D0 (en) | 2004-11-29 | 2004-12-29 | Novartis Ag | Organic compounds |
| GB0507577D0 (en) | 2005-04-14 | 2005-05-18 | Novartis Ag | Organic compounds |
| GB0514809D0 (en) | 2005-07-19 | 2005-08-24 | Glaxo Group Ltd | Compounds |
| RU2442771C2 (ru) | 2005-08-08 | 2012-02-20 | Арджента Дискавери Лтд | Производные бицикло[2,2,1]гепт-7-иламина и их применения |
| GB0516313D0 (en) | 2005-08-08 | 2005-09-14 | Argenta Discovery Ltd | Azole derivatives and their uses |
| MY144906A (en) | 2005-10-21 | 2011-11-30 | Novartis Ag | Human antibodies against il13 and therapeutic uses |
| GB0601951D0 (en) | 2006-01-31 | 2006-03-15 | Novartis Ag | Organic compounds |
| CA2643097C (en) | 2006-03-20 | 2012-03-13 | Pfizer Limited | Amine derivatives |
| AR060607A1 (es) | 2006-04-21 | 2008-07-02 | Novartis Ag | Derivados de purina,composiciones farmaceuticas que los contienen, metodo de preparacion y usos en enfermedades obstructivas o inflamatorias de las vias respiratorias. |
| KR20090030347A (ko) | 2006-07-19 | 2009-03-24 | 아스트라제네카 아베 | 신규 트리시클릭 스피로피페리딘 화합물, 이들의 합성 및 이들의 케모킨 수용체 활성의 조절제로서의 용도 |
| TW200825084A (en) | 2006-11-14 | 2008-06-16 | Astrazeneca Ab | New compounds 521 |
| CA2672446A1 (en) | 2006-12-19 | 2008-06-26 | Astrazeneca Ab | Quinuclidinol derivatives as muscarinic receptor antagonists |
| US20080176901A1 (en) | 2007-01-10 | 2008-07-24 | Irm Llc | Compounds and compositions as channel activating protease inhibitors |
| EA200901082A1 (ru) | 2007-02-09 | 2010-02-26 | Айрм Ллк | Соединения и композиции в качестве ингибиторов протеазы, активирующей каналы |
| AU2008248598B2 (en) | 2007-05-07 | 2011-11-17 | Novartis Ag | Organic compounds |
| ES2654395T3 (es) | 2007-12-10 | 2018-02-13 | Novartis Ag | Análogos de amilorida espirocíclicos como bloqueantes de ENaC |
| JP5584138B2 (ja) | 2008-01-11 | 2014-09-03 | ノバルティス アーゲー | キナーゼ阻害剤としてのピリミジン類 |
| JP4837800B2 (ja) | 2008-05-13 | 2011-12-14 | アストラゼネカ・アクチエボラーグ | ムスカリンｍ３受容体アンタゴニストとしてのキヌクリジン誘導体 |
| CA2721065C (en) | 2008-05-27 | 2016-09-27 | Astrazeneca Ab | Phenoxypyridinylamide derivatives and their use as pde4 inhibitors |
| EP2300010B1 (en) | 2008-06-10 | 2015-03-04 | Novartis AG | Pyrazine derivatives as epithelial sodium channel blockers |
| US8236786B2 (en) | 2008-08-07 | 2012-08-07 | Pulmagen Therapeutics (Inflammation) Limited | Respiratory disease treatment |
| WO2010067102A1 (en) | 2008-12-09 | 2010-06-17 | Astrazeneca Ab | Diazaspiro [5.5] undecane derivatives and related compounds as muscarinic-receptor antagonists and beta-adrenoreceptor agonists for the treatment of pulmonary disorders |
| WO2010076553A1 (en) | 2008-12-30 | 2010-07-08 | Dr. Reddy's Laboratories Ltd | Sulfonamide compounds for the treatment of respiratory disorders |
| WO2010150014A1 (en) | 2009-06-24 | 2010-12-29 | Pulmagen Therapeutics (Inflammation) Limited | 5r- 5 -deuterated glitazones for respiratory disease treatment |
| JP5801997B2 (ja) | 2009-07-07 | 2015-10-28 | ファイザー・リミテッドＰｆｉｚｅｒ Ｌｉｍｉｔｅｄ | 薬品の組合せを吸入するための投薬ユニット、投薬ユニットのパック、および吸入器 |
| MX2012004792A (es) | 2009-10-22 | 2013-02-01 | Vertex Pharma | Composiciones para el tratamiento de fibrosis quistica y otras enfermedades cronicas. |
| GB0918924D0 (en) | 2009-10-28 | 2009-12-16 | Vantia Ltd | Azaindole derivatives |
| GB0918922D0 (en) | 2009-10-28 | 2009-12-16 | Vantia Ltd | Aminopyridine derivatives |
| GB0918923D0 (en) | 2009-10-28 | 2009-12-16 | Vantia Ltd | Aminothiazole derivatives |
| WO2011061527A1 (en) | 2009-11-17 | 2011-05-26 | Astrazeneca Ab | Combinations comprising a glucocorticoid receptor modulator for the treatment of respiratory diseases |
| WO2011098746A1 (en) | 2010-02-09 | 2011-08-18 | Pulmagen Therapeutics (Inflammation) Limited | Crystalline acid addition salts of ( 5r) -enanti0mer of pioglitazone |
| GB201002243D0 (en) | 2010-02-10 | 2010-03-31 | Argenta Therapeutics Ltd | Respiratory disease treatment |
| GB201002224D0 (en) | 2010-02-10 | 2010-03-31 | Argenta Therapeutics Ltd | Respiratory disease treatment |
| US8247436B2 (en) | 2010-03-19 | 2012-08-21 | Novartis Ag | Pyridine and pyrazine derivative for the treatment of CF |
| WO2012034095A1 (en) | 2010-09-09 | 2012-03-15 | Irm Llc | Compounds and compositions as trk inhibitors |
| UY33597A (es) | 2010-09-09 | 2012-04-30 | Irm Llc | Compuestos y composiciones como inhibidores de la trk |
| US8372845B2 (en) | 2010-09-17 | 2013-02-12 | Novartis Ag | Pyrazine derivatives as enac blockers |
| GB201016912D0 (en) | 2010-10-07 | 2010-11-24 | Astrazeneca Ab | Novel combination |
| JP5959541B2 (ja) | 2011-02-25 | 2016-08-02 | ノバルティス アーゲー | Ｔｒｋ阻害剤としてのピラゾロ［１，５−ａ］ピリジン |
| AR085509A1 (es) | 2011-03-09 | 2013-10-09 | Bayer Cropscience Ag | Indol- y bencimidazolcarboxamidas como insecticidas y acaricidas |
| EA022342B1 (ru) | 2011-06-10 | 2015-12-30 | КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. | Соединения с активностью антагонистов мускариновых рецепторов и агонистов адренергического рецептора бета2 |
| UY34305A (es) | 2011-09-01 | 2013-04-30 | Novartis Ag | Derivados de heterociclos bicíclicos para el tratamiento de la hipertensión arterial pulmonar |
| WO2013038378A1 (en) | 2011-09-16 | 2013-03-21 | Novartis Ag | Pyridine amide derivatives |
| ES2882807T3 (es) | 2011-09-16 | 2021-12-02 | Novartis Ag | Heterociclil carboxamidas N-sustituidas |
| WO2013038381A1 (en) | 2011-09-16 | 2013-03-21 | Novartis Ag | Pyridine/pyrazine amide derivatives |
| US9034879B2 (en) | 2011-09-16 | 2015-05-19 | Novartis Ag | Heterocyclic compounds for the treatment of CF |
| WO2013038373A1 (en) | 2011-09-16 | 2013-03-21 | Novartis Ag | Pyridine amide derivatives |
| US8809340B2 (en) | 2012-03-19 | 2014-08-19 | Novartis Ag | Crystalline form |
| AR093832A1 (es) | 2012-12-06 | 2015-06-24 | Chiesi Farm Spa | COMPUESTOS CON ACTIVIDAD ANTAGONISTA DE LOS RECEPTORES MUSCARINICOS Y ACTIVIDAD AGONISTA DEL RECEPTOR b2 ADRENERGICO |
| HUE051394T2 (hu) | 2012-12-06 | 2021-03-01 | Chiesi Farm Spa | Muszkarin receptor antagonista és béta2 adrenerg receptor agonista aktivitással rendelkezõ vegyületek |
| US9073921B2 (en) | 2013-03-01 | 2015-07-07 | Novartis Ag | Salt forms of bicyclic heterocyclic derivatives |
| AR099336A1 (es) | 2014-02-17 | 2016-07-13 | Bayer Cropscience Ag | Indol- y bencimidazolcarboxamidas como insecticidas y acaricidas |
| EA201692140A1 (ru) | 2014-04-24 | 2017-04-28 | Новартис Аг | Производные аминопиридина в качестве ингибиторов фосфатидилинозитол 3-киназы |
| WO2015162461A1 (en) | 2014-04-24 | 2015-10-29 | Novartis Ag | Pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors |
| MX2016013812A (es) | 2014-04-24 | 2017-03-09 | Novartis Ag | Derivados de amino-pirazina como inhibidores de fosfatidil-inositol-3-cinasa. |
| JP2022537667A (ja) | 2019-06-10 | 2022-08-29 | ノバルティス アーゲー | Ｃｆ、ｃｏｐｄ、及び気管支拡張症の治療のためのピリジン及びピラジン誘導体 |
| EP4021572A1 (en) | 2019-08-28 | 2022-07-06 | Novartis AG | Substituted 1,3-phenyl heteroaryl derivatives and their use in the treatment of disease |
| US20230293430A1 (en) | 2020-06-26 | 2023-09-21 | Mylan Pharma Uk Limited | Formulations including 5-[3-(3-hydroxyphenoxy)azetidin-1-yl]-5-methyl-2,2-diphenylhexanamide |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE154935T1 (de) * | 1993-06-14 | 1997-07-15 | Pfizer | Zweite amine als antidiabetische mittel und für die behandlung von fettleibigkeit |
| EP0801060A1 (en) * | 1996-04-09 | 1997-10-15 | Pfizer Inc. | Heterocyclic Beta-3 Adrenergenic Agonists |
| EP0822185A1 (en) * | 1996-07-31 | 1998-02-04 | Pfizer Inc. | B-3-adrenergic agonists as antidiabetic and antiobesity agents |
-
2003
- 2003-10-06 DE DE60320439T patent/DE60320439T2/de not_active Expired - Lifetime
- 2003-10-06 AP AP2005003283A patent/AP2005003283A0/xx unknown
- 2003-10-06 EA EA200500618A patent/EA200500618A1/ru unknown
- 2003-10-06 ES ES03751095T patent/ES2302938T3/es not_active Expired - Lifetime
- 2003-10-06 PL PL03376396A patent/PL376396A1/xx unknown
- 2003-10-06 EP EP03751095A patent/EP1556034B1/en not_active Expired - Lifetime
- 2003-10-06 JP JP2005501006A patent/JP4490911B2/ja not_active Expired - Fee Related
- 2003-10-06 MX MXPA05003866A patent/MXPA05003866A/es not_active Application Discontinuation
- 2003-10-06 CA CA2499314A patent/CA2499314C/en not_active Expired - Fee Related
- 2003-10-06 AU AU2003269316A patent/AU2003269316A1/en not_active Abandoned
- 2003-10-06 AT AT03751095T patent/ATE392206T1/de not_active IP Right Cessation
- 2003-10-06 BR BR0315234-0A patent/BR0315234A/pt not_active IP Right Cessation
- 2003-10-06 OA OA1200500099A patent/OA12938A/en unknown
- 2003-10-06 WO PCT/IB2003/004441 patent/WO2004032921A1/en not_active Ceased
- 2003-10-06 KR KR1020057006090A patent/KR20050047552A/ko not_active Ceased
- 2003-10-09 AR ARP030103677A patent/AR041566A1/es unknown
- 2003-10-09 TW TW092128121A patent/TW200424171A/zh unknown
- 2003-10-09 PE PE2003001024A patent/PE20040775A1/es not_active Application Discontinuation
- 2003-10-10 PA PA20038586001A patent/PA8586001A1/es unknown
- 2003-10-10 UY UY28013A patent/UY28013A1/es not_active Application Discontinuation
-
2005
- 2005-03-17 IS IS7751A patent/IS7751A/is unknown
- 2005-03-17 NO NO20051406A patent/NO20051406L/no unknown
- 2005-04-08 CO CO05032119A patent/CO5550421A2/es not_active Application Discontinuation
- 2005-04-11 MA MA28210A patent/MA27452A1/fr unknown
- 2005-05-05 EC EC2005005780A patent/ECSP055780A/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2006511596A5 (enExample) | ||
| JP2006526613A5 (enExample) | ||
| CA2499314A1 (en) | Indole derivatives as beta-2 agonists | |
| JP2009530364A5 (enExample) | ||
| CA2643097A1 (en) | Amine derivatives | |
| AU738134B2 (en) | Amidocarboxylic acid derivatives | |
| US20100016274A1 (en) | Beta-lactam cannabinoid receptor modulators | |
| JP2008512470A5 (enExample) | ||
| HRP20180116T1 (hr) | (2s)-n-[(1s)-1-cijano-2-feniletil]-1,4-oksazepan-2-karboksamidi kao inhibitori dipeptidil peptidaze i | |
| CN1474818A (zh) | 含有稠合杂环化合物或其盐的糖尿病预防或治疗药 | |
| US20050245575A1 (en) | 1-((5-aryl-1,2,4-oxadiazol-3-yl) benzyl)azetidine-3-carboxylates and 1-((5-aryl-1,2,4-oxadiazol-3-yl)benzyl) pyrrolidine-3-carboxylates as edg receptor agonists | |
| JP2013526520A5 (enExample) | ||
| RU2009134512A (ru) | Гидрохлоридная соль 5-[3-(3-гидроксифенокси)азетедин-1-ил]-5-метил-2,2-дифенилгексанамида | |
| JP2007502830A (ja) | キャップ化ピラジノイルグアニジンナトリウムチャネルブロッカー | |
| JP2011511835A5 (enExample) | ||
| JP2009533473A5 (enExample) | ||
| JP2008510708A (ja) | 環式アミド及びエステルピラジノイルグアニジンナトリウムチャネル遮断薬 | |
| JP2003516314A (ja) | ライノウイルス感染症におけるｃｓａｉｄの使用 | |
| HRP20100035T1 (hr) | Kristalni oblici bifenilnog spoja | |
| JP2014508720A5 (enExample) | ||
| KR102563039B1 (ko) | 세균 이차 감염의 치료 및/또는 예방에 사용하기 위한 il-8 억제제 | |
| JP2023126245A5 (enExample) | ||
| JP2016505582A5 (enExample) | ||
| JP2010526801A5 (enExample) | ||
| JP2005500370A5 (enExample) |